Striebel H W, Wilker E
Klinik für Anästhesiologie und operative Intensivmedizin, Klinikum Steglitz, Freie Universität Berlin.
Anasthesiol Intensivmed Notfallmed Schmerzther. 1993 May;28(3):168-73. doi: 10.1055/s-2007-998900.
40 patients who had undergone total hip replacement were included in a randomised prospective study. Postoperative pain management was performed with a continuous 3-in-1 block combined with demand-adapted intravenous meperidine titration (3-in-1 catheter group; n = 20) or by demand-adapted intravenous meperidine titration alone (control group; n = 20). The 3-in-1 catheter was placed before the start of anesthesia, and the patients received 30 ml 0.5% bupivacaine via this catheter. A second dose of 30 ml 0.5% bupivacaine was injected 10 min after postanaesthetic recovery. In the control group intravenous meperidine titration was initiated if the patients required pain relief. Subjective pain intensity was evaluated over a 6-hour period by means of the visual analogue scale. Bupivacaine plasma concentrations were determined in 18 patients at 30, 60, 120, and 180 min after the first postoperative injection of bupivacaine. Good pain control was achieved in both groups. The patients in the control group required a mean of 80.8 +/- 49.9 mg meperidine. The 3-in-1 block group required significantly less meperidine (54.3 +/- 44.5 mg). Mean bupivacaine plasma levels ranged between 0.75 and 1.33 micrograms/ml. Placement of the 3-in-1 catheters was without complications. For the management of postoperative pain following total hip replacement a continuous 3-in-1 block alone was often insufficient but postoperative meperidine requirements were significantly reduced (p < 0.05). Toxic bupivacaine plasma concentrations were not measured.
40例行全髋关节置换术的患者被纳入一项随机前瞻性研究。术后疼痛管理采用连续三合一阻滞联合按需调整静脉注射哌替啶滴定法(三合一导管组;n = 20)或仅采用按需调整静脉注射哌替啶滴定法(对照组;n = 20)。在麻醉开始前放置三合一导管,患者通过该导管接受30 ml 0.5%布比卡因。麻醉恢复后10分钟注射第二剂30 ml 0.5%布比卡因。在对照组中,如果患者需要缓解疼痛,则开始静脉注射哌替啶滴定。通过视觉模拟量表在6小时内评估主观疼痛强度。在首次术后注射布比卡因后30、60、120和180分钟,对18例患者测定布比卡因血浆浓度。两组均实现了良好的疼痛控制。对照组患者平均需要80.8±49.9 mg哌替啶。三合一阻滞组所需哌替啶明显较少(54.3±44.5 mg)。布比卡因平均血浆水平在0.75至1.33微克/毫升之间。放置三合一导管无并发症。对于全髋关节置换术后的疼痛管理,单独的连续三合一阻滞往往不足,但术后哌替啶需求量显著减少(p < 0.05)。未测量布比卡因中毒血浆浓度。